title: Rhinitis medicamentosa: a review of causes and treatment.
abstract: Rhinitis medicamentosa (RM) is a drug-induced, nonallergic form of rhinitis that is associated with prolonged use of topical vasoconstrictors, i.e. local decongestants. Symptoms are exacerbated by the preservative benzalkonium chloride (BKC) in the nasal preparations. Nasal stuffiness is caused by rebound swelling of the mucosa when the decongestive effect of the drug has disappeared. To alleviate this symptom, patients gradually start using larger doses of the vasoconstrictor more frequently. In many cases, the patient is unaware of the condition, thus entering a vicious circle of self-treatment. Careful questioning is required during consultation to establish diagnosis. The pathophysiology of the condition is unclear; however, vasodilatation and intravascular edema have both been implicated. Management of RM requires withdrawal of topical decongestants to allow the damaged nasal mucosa to recover, followed by treatment of the underlying nasal disease. Topical corticosteroids such as budesonide and fluticasone propionate should be used to alleviate rebound swelling of the nasal mucosa. Where possible, avoiding exposure to BKC is recommended.
authors.affiliation: Karolinksa University Hospital, Solna, 171 76 Stockholm, Sweden. peter.graf@karolinska.se
authors.forename: Peter
authors.initials: P
authors.lastname: Graf
mesh_terms: D001548:Benzalkonium Compounds / Q000009:adverse effects; D006801:Humans; D014663:Nasal Decongestants / Q000009:adverse effects; D009297:Nasal Mucosa / Q000473:pathology / Q000502:physiology; D010353:Patient Education as Topic; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects; D012220:Rhinitis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors
chemical_list: D001548:Benzalkonium Compounds; D014663:Nasal Decongestants; D011310:Preservatives, Pharmaceutical